10-Q quarterly report · filed Nov 4, 2026

BIOCRYST PHARMACEUTICALS INC (BCRX) Q3 2026 10-Q Quarterly Report

Short answer

BIOCRYST PHARMACEUTICALS INC (BCRX) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $180M (up 13.1% year over year) with net income of $38M.

Q3 2026 key financials · XBRL

Revenue
$180M
+13.1% YoY · −17.4% QoQ
Net income
$38M
+193.9% YoY · −51.6% QoQ
Operating margin
29.6%
EPS (diluted)
$0.18
+200.0% YoY · −53.8% QoQ

Source: XBRL data from the BIOCRYST PHARMACEUTICALS INC (BCRX) Q3 2026 10-Q on SEC EDGAR. USD.

BIOCRYST PHARMACEUTICALS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $180.3M, up $20.9M YoY from $159.4M
  • ORLADEYO revenue $174.8M, up $29.6M YoY excluding European business
  • R&D expense $58.2M vs $44.6M, driven by $18.0M navenibart spending
  • Liquidity $375.0M; operating cash flow $75.5M, up from $55.4M
  • Near-term focus: external innovation, cost containment, ORLADEYO commercialization; specialty-pharmacy inventory benefit in upper teens of millions

Risk Factors

  • Newly added regulatory risk: Annora’s January 2026 Paragraph IV notice challenges four ORLADEYO patents expiring May 2040
  • Most materially updated strategic risk: Astria acquisition added navenibart execution uncertainty and $400 million Blackstone-funded obligations
  • Operational risk: Transition to a new sole-source ORLADEYO specialty pharmacy could disrupt patient shipments and quarterly revenue timing
  • Financial risk: Blackstone Term Loans mature January 23, 2031 with quarterly interest tied to SOFR plus 4.50%
  • Legal risk: ORLADEYO patent litigation against Annora remains stayed until 2031 with outcome and potential loss currently indeterminable

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other BIOCRYST PHARMACEUTICALS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.